> News > Glenmark Pharmaceuticals S.A. to Invest in New Translational Research Group at Biopôle Lausanne-Epalinges
Glenmark Pharmaceuticals S.A. to Invest in New Translational Research Group at Biopôle Lausanne-Epalinges
LA CHAUX-DE-FONDS, Switzerland and PARAMUS, N.J., March 6, 2018 /PRNewswire/ -- Glenmark Pharmaceuticals announced today it will enhance its capabilities in translational research by opening a new discovery centre at the Biopôle campus of Lausanne (https://www.biopole.ch/en/). Glenmark will continue to invest in, and operate its process development and biologics manufacturing centre out of La-Chaux-de-Fonds, Neuchȃtel. Approximately 20% of current employees will be housed in the discovery group at Lausanne.
"The Biopôle is one of the most vibrant ecosystems for life sciences innovation in Europe. This expansion opens a universe of opportunity to foster our innovation capabilities by collaborating with the world class research centres, academic groups and hospitals in the Lausanne vicinity.